Work

Reversal of promoter hypermethylation with targeted DNA methyltransferase inhibitors in gastric cancer

Year: 2026
Type: article
Abstract: Gastric cancer is one of the leading causes of cancer-related mortality worldwide, and DNA hypermethylation, particularly CDKN2A/p16 promoter hypermethylation, plays a critical role in tumor suppressor gene silencing during gastric carcinogenesis. DNA methyltransferase (DNMT) inhibitors have therefore been explored as epigenetic agents in gastric cancer; however, their biological effects and regulatory consequences remain incompletely understood. This thesis aimed to investigate how DNMT inhibition modulates DNA methylation, gene expression, and regulatory networks in gastric cancer, with a specific focus on CDKN2A/p16 and CDKN2A-associated gene networks under DNMT inhibitor treatment. To address this objective, multiple gastric cancer cell lines were used to evaluate the effects of three DNMT inhibitors, decitabine, RG108, and GSK3685032, on total DNA methylation, CDKN2A(p16) promoter methylation, gene expression, cell-cycle progression, and histone modification. At low concentrations, DNMT inhibitors reduced total and promoter-specific DNA methylation and increased CDKN2A(p16) expression, resulting in cell-cycle arrest. In contrast, higher concentrations produced a paradoxical increase in DNA methylation at both total and gene-specific levels, accompanied by reduced CDKN2A(p16) expression. These dose-dependent responses were associated with increased expression of DNMT3B and, in some cases, TET enzymes. These findings suggest that, if translatable to gastric cancer treatment, lower doses of decitabine and GSK3685032 may enhance CDKN2A(p16) expression, whereas higher doses may attenuate CDKN2A(p16) expression and potentially reduce therapeutic effectiveness. To extend these observations beyond individual gene responses, integrative multi-database analysis, bioinformatic analysis, and dynamic DNMT inhibitor dose validation were employed to define CDKN2A-centered regulatory networks in gastric cancer. From large public datasets, a 20-gene CDKN2A-associated panel with clinical relevance and network support was identified and evaluated through network reconstruction and survival analyses. Dynamic dose-response validation of gene expression further supported TRIB3, GET4, and PDE4D as connected components within this network. Among these, TRIB3 emerged as the most consistently supported candidate, based on convergent clinical, network, and DNMT inhibitor–responsive expression evidence, indicating that TRIB3 is a tightly coupled component of the CDKN2A-driven network and a potential co-targeting candidate. Together, this work demonstrates that DNMT inhibitor responses in gastric cancer are shaped by coordinated, dose-dependent regulation within CDKN2A-centered gene networks rather than simple gene-level effects.
Author: Luo, Wenxia
Language: English
Open Access status: green
OpenAlex ID: W7208798338
FWCI:
Cites: 238
Cited by:
Related to: 10